Uflex Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Volume-led recovery, pricing still weak: Consolidated volume grew 8% YoY, with film volumes up 13.7%, but domestic BOPET overcapacity continues to suppress realizations and margins.
• Europe turns a corner on costs, not demand: A new power contract cut energy costs by ~40% in Hungary and Poland, providing a structural tailwind even as European selling prices remain under pressure from Indian exports.
• Nigeria and Egypt deliver growth and pain: Nigeria captured >50% market share and is ramping toward 85% utilization, but combined currency devaluations hit the P&L for ₹871 crores in FY24, almost entirely as a non-cash translation loss.
• Aseptic packaging is the star, and it is capacity-constrained: Asepto ran above rated capacity at ~740 crore packs, holds a 20%+ EBITDA margin that management calls permanent, and a new high-speed machine plus bottlenecking to 1,200 crore packs promises a step-change in revenue.
• What to watch next quarter: Whether the 9–10% domestic BOPET price hike sticks and mirrors internationally, the pace of the Nigeria ramp-up, and the first contribution from the new Panipat PET chips and Egypt PCR plants.

Volume & Demand Recovery

• Broad-based volume growth: All business segments contributed to the 8% consolidated volume increase; the film business led with 13.7% YoY volume growth, and value-added packaging grew 8.7% QoQ.
• Rural demand turning: Management noted rural demand picking up at the fag end of Q4, creating a possibility of further volume growth in packaging film, flexible packaging and aseptic packaging as FY25 begins.
• Red Sea disruption as a net positive: The crisis helped local producers capture volumes and higher margins as customers worried about higher freight costs and longer transit times, pulling demand toward regional supply.
• U.S. and Mexico running hot: Q4 was very good on volumes; the region is self-sufficient with own production but still had to import from India, Nigeria and other facilities to meet demand, indicating market size captured is well beyond local manufacturing capability.
• India capacity deliberately underutilized: Some old, high-cost facilities are not being operated because domestic prices are not remunerative; full utilization depends on pricing improvement, tentatively pegged at Q3 or Q4 of FY25.

Rajesh Bhatia: "I think Q4 sets a tone for FY '25, which is extremely, extremely positive note, both on the volume and the revenue side."

Pricing & Overcapacity

• Domestic BOPET market still subdued: Volumes are good but overcapacity has eroded selling prices and margins; the industry has seen a price collapse from COVID-era peaks of ₹250 per kg to around ₹100 today, though raw materials have also corrected.
• India excess capacity hurts Europe: Overcapacity in India has added pressure on realizations in Europe, which was already reeling from Ukraine-war energy prices; European volumes are coming back but margin pressure persists.
• A 9–10% price hike offers hope: A recent industry-wide BOPET price increase in India is expected to help domestic markets and reduce the pressure of exports from India to Europe and America, since better domestic prices reduce the urge to export and the associated working capital burden.
• International mirroring expected: Management expects the Indian price hike to mirror in international markets during FY25, which would improve realizations across geographies.

Rajesh Bhatia: "In the COVID period, during the COVID period, people have spent INR250 per kg on the packaging films. And today, then the price is INR100 only. Of course, the raw materials have also corrected. But then that's the kind of delta that this world has been post COVID and during the COVID period, in the packaging films and their raw material side."

Geographic Performance

• Currency impact is largely non-cash: The very large part of the ₹871 crores FY24 forex loss is notional translation loss from converting Naira to dollar to INR; an insignificant portion is actual cash loss.

Aseptic Packaging: The High-Margin Growth Engine

• Running above rated capacity: Asepto sold ~740 crore packs in FY24 against a rated capacity of 700 crore packs, making capacity constraints the binding limit on growth.
• Bottlenecking to 1,200 crore packs: Production capability is being expanded from 700 crore to ~1,200 crore packs per year; the ramp-up is expected by September or October at the latest, with full run-rate by January, giving FY25 one quarter at the higher number.
• New high-speed machine demonstrated: A machine capable of 25,000 packs per hour (vs the earlier 10,000) was showcased at Drupa in Germany; this will augment volumes to the 1,200 crore target much faster given its speed.
• Margin stability is a management commitment: Asepto EBITDA margin is 20%+ currently, with export and domestic margins largely the same (1–2% variation depending on market dynamics); management states it will always remain a 20%+ margin business.

Rajesh Bhatia: "Asepto will always remain 20% plus margin business. It's currently 20% plus and it will remain at 20% plus."

Cost Structure & Operational Efficiency

• European power costs structurally lower: New power purchase contracts in Hungary and Poland, effective January 1, reduced power costs by as much as 40% versus the prior contract; these contracts will cover all of FY25, with power prices in Europe now stable after Russia-Ukraine war fluctuations.
• Dharwad power savings imminent: A ~40% reduction in power costs at the Dharwad facility, worth ₹35–40 crores annually, is expected to start reflecting from June onward; the new power supply had not yet commenced as of the call.
• Poland production ramping: Q4 production in Poland was up 27% QoQ, with substantial headroom remaining to take numbers up further; the pace depends on European demand recovery.
• Nigeria utilization lever: Ramping Nigeria from 67% to ~85% utilization is targeted within about a quarter, though management flagged some constraints exist; higher utilization will improve fixed-cost absorption in a market where Uflex already commands >50% share.

Strategy: Recycling vs Biodegradable Films

• Recycling is not the strategic priority: Management explicitly stated they do not intend to be big in the recycling business, viewing it as a localized opportunity dependent on government-driven regulations that may take a couple of years to materialize.
• Biodegradable films are the big bet: Uflex sees biodegradable films as a centralized opportunity where enzymes can be added to make films biodegradable; companies using such films do not carry further liability beyond that, making it a scalable, differentiated product.
• Leadership ambition in biodegradable: Management wants to be a leader in the biodegradable films business, positioning it as the primary sustainability-driven growth vector rather than mechanical recycling.

Rajesh Bhatia: "End of the day if you ask us do we have the intention to be big in this business? The answer is no. The answer for us is we want to be a leader in the biodegradable films business."

Guidance & Commitments

Key Metrics